Geode Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $23.4M | Buy |
1,342,387
+81,910
| +6% | +$1.43M | ﹤0.01% | 1880 |
|
|
2025
Q1 | $15.9M | Buy |
1,260,477
+22,321
| +2% | +$281K | ﹤0.01% | 2024 |
|
|
2024
Q4 | $13.1M | Buy |
1,238,156
+3,351
| +0.3% | +$35.4K | ﹤0.01% | 2194 |
|
|
2024
Q3 | $17.9M | Buy |
1,234,805
+38,927
| +3% | +$565K | ﹤0.01% | 2033 |
|
|
2024
Q2 | $10.2M | Buy |
1,195,878
+319,207
| +36% | +$2.72M | ﹤0.01% | 2316 |
|
|
2024
Q1 | $8.96M | Buy |
876,671
+11,802
| +1% | +$121K | ﹤0.01% | 2389 |
|
|
2023
Q4 | $4.74M | Buy |
864,869
+61,528
| +8% | +$337K | ﹤0.01% | 2726 |
|
|
2023
Q3 | $3.04M | Buy |
803,341
+149,746
| +23% | +$566K | ﹤0.01% | 2898 |
|
|
2023
Q2 | $4.38M | Buy |
653,595
+249,991
| +62% | +$1.67M | ﹤0.01% | 2758 |
|
|
2023
Q1 | $2.63M | Buy |
403,604
+71,408
| +21% | +$465K | ﹤0.01% | 2918 |
|
|
2022
Q4 | $2.83M | Buy |
332,196
+107,812
| +48% | +$919K | ﹤0.01% | 2924 |
|
|
2022
Q3 | $1.18M | Buy |
224,384
+732
| +0.3% | +$3.86K | ﹤0.01% | 3306 |
|
|
2022
Q2 | $948K | Sell |
223,652
-138,988
| -38% | -$589K | ﹤0.01% | 3452 |
|
|
2022
Q1 | $1.27M | Sell |
362,640
-29,472
| -8% | -$103K | ﹤0.01% | 3500 |
|
|
2021
Q4 | $2.61M | Buy |
392,112
+207,000
| +112% | +$1.38M | ﹤0.01% | 3249 |
|
|
2021
Q3 | $1.85M | Sell |
185,112
-35,576
| -16% | -$355K | ﹤0.01% | 3387 |
|
|
2021
Q2 | $6.82M | Buy |
220,688
+2,067
| +0.9% | +$63.8K | ﹤0.01% | 2724 |
|
|
2021
Q1 | $9.54M | Buy |
218,621
+199,391
| +1,037% | +$8.7M | ﹤0.01% | 2397 |
|
|
2020
Q4 | $891K | Buy |
+19,230
| New | +$891K | ﹤0.01% | 3399 |
|